^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-1916

    i
    Other names: SHR-1916
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    9ms
    SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy. (PubMed, Drug Des Devel Ther)
    SHR-1916 exhibited excellent cellular selectivity, anti-tumor efficacies, and improved pharmacokinetics. It has the potential to serve as a novel immunotherapeutic agent designed to enhance IL-2's immune-stimulating activities and promote its tolerability while reducing the immunoregulatory function of Treg cells.
    PK/PD data • Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    SHR-1916
    almost2years
    A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=11, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=50 --> 11 | Recruiting --> Terminated; R&d strategy adjustment
    Enrollment change • Trial termination • Metastases
    |
    SHR-1916
    over4years
    A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD8 (cluster of differentiation 8)
    |
    SHR-1916
    over4years
    A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    Clinical • New P1 trial
    |
    CD8 (cluster of differentiation 8)
    |
    SHR-1916